CORT:NSD-Corcept Therapeutics Incorporated (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 70.46

Change

-0.28 (-0.40)%

Market Cap

USD 7.57B

Volume

1.33M

Analyst Target

USD 15.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-15.21 (-3.38%)

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

+2.41 (+0.43%)

USD 65.38B
ARGX argenx NV ADR

+7.82 (+1.27%)

USD 35.43B
ALNY Alnylam Pharmaceuticals Inc

+6.74 (+2.50%)

USD 30.51B
SMMT Summit Therapeutics PLC

+0.09 (+0.37%)

USD 27.07B
ONC BeiGene, Ltd.

-9.50 (-3.93%)

USD 26.35B
RPRX Royalty Pharma Plc

+0.64 (+1.99%)

USD 18.40B
INSM Insmed Inc

+0.41 (+0.60%)

USD 12.52B
INCY Incyte Corporation

-0.06 (-0.10%)

USD 11.72B
BMRN Biomarin Pharmaceutical Inc

-0.32 (-0.54%)

USD 11.50B

ETFs Containing CORT

ABLS Abacus FCF Small Cap Lead.. 11.53 % 0.00 %

N/A

N/A
PSCH Invesco S&P SmallCap Heal.. 4.67 % 0.29 %

+0.23 (+0.01%)

USD 0.15B
JSML Janus Henderson Small Cap.. 3.81 % 0.50 %

+0.42 (+0.01%)

USD 0.17B
JSMD Janus Henderson Small/Mid.. 1.82 % 0.50 %

+0.22 (+0.01%)

USD 0.44B
SEIS SEI Select Small Cap ETF 1.40 % 0.00 %

+0.11 (+0.01%)

USD 0.22B
VTWG Vanguard Russell 2000 Gro.. 0.75 % 0.20 %

+0.82 (+0.01%)

USD 0.90B
SMAX iShares Large Cap Max Buf.. 0.55 % 0.00 %

+0.03 (+0.01%)

USD 0.09B
FLDZ Listed Funds Trust 0.50 % 0.00 %

+0.13 (+0.01%)

USD 3.65M
XRS2:SW Xtrackers Russell 2000 UC.. 0.38 % 0.00 %

-0.50 (0.01%)

USD 1.82B
VTWO Vanguard Russell 2000 Ind.. 0.38 % 0.15 %

+0.23 (+0.01%)

USD 10.97B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

-0.05 (0.01%)

N/A
IJR iShares Core S&P Small-Ca.. 0.00 % 0.07 %

+0.14 (+0.01%)

USD 70.99B
IJT iShares S&P Small-Cap 600.. 0.00 % 0.25 %

+0.24 (+0.01%)

USD 5.40B
JPSE JPMorgan Diversified Retu.. 0.00 % 0.29 %

+0.07 (+0.01%)

USD 0.41B
SPSM SPDR® Portfolio S&P 600 .. 0.00 % 0.06 %

+0.03 (+0.01%)

USD 9.96B
VRTGX Vanguard Russell 2000 Gro.. 0.00 % 0.00 %

N/A

USD 1.19B
VRTIX Vanguard Russell 2000 Ind.. 0.00 % 0.00 %

-2.23 (0.01%)

USD 10.02B
SAA ProShares Ultra SmallCap6.. 0.00 % 0.95 %

N/A

USD 0.02B
GSSC Goldman Sachs ActiveBeta.. 0.00 % 0.20 %

+0.18 (+0.01%)

USD 0.48B
ISP6:LSE iShares III Public Limite.. 0.00 % 0.00 %

+7.00 (+0.01%)

USD 2.48B
R2US:PA SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

-0.18 (0.01%)

USD 4.13B
BKSE BNY Mellon ETF Trust - BN.. 0.00 % 0.00 %

+0.33 (+0.01%)

USD 0.10B
FORH Formidable ETF 0.00 % 0.00 %

+0.17 (+0.01%)

USD 0.02B
QVMS Invesco Exchange-Traded F.. 0.00 % 0.00 %

-0.13 (0.01%)

USD 0.16B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 39.83% 92% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.83% 92% A 94% A
Trailing 12 Months  
Capital Gain 177.40% 97% N/A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 177.40% 97% N/A 97% N/A
Trailing 5 Years  
Capital Gain 424.65% 97% N/A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 424.65% 97% N/A 95% A
Average Annual (5 Year Horizon)  
Capital Gain 30.67% 74% C 83% B
Dividend Return 30.67% 74% C 83% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 51.69% 61% D- 35% F
Risk Adjusted Return 59.34% 97% N/A 84% B
Market Capitalization 7.57B 97% N/A 92% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.